Get the Daily Brief
Latest Biotech News
Zanzalintinib plus Tecentriq cuts death risk 20% — Exelixis unveils Phase 3 data
Exelixis presented Phase 3 data showing its oral TKI zanzalintinib in combination with Roche’s Tecentriq reduced the risk of death by 20% versus the standard comparator in previously treated...
NewLimit raises $45M with Lilly Ventures backing — anti‑aging play
NewLimit closed a $45 million financing round that included investments from Lilly Ventures and S32, positioning the company to advance its anti‑aging programs. The startup, cofounded by...
FDA approves Roche’s Gazyva for lupus nephritis
The FDA granted approval for Roche’s CD20 antibody Gazyva (obinutuzumab) to treat lupus nephritis, the company said. The decision adds a targeted B‑cell therapy to the limited toolkit for...
India’s top court allows Natco to sell generic Evrysdi — Roche’s bid fails
India’s Supreme Court dismissed Roche’s petition and allowed Natco Pharma to sell a generic version of Evrysdi, the STAT report said. The court’s decision cleared the path for much lower‑cost...
AstraZeneca and Gilead square off in triple‑negative breast cancer — ADCs vie for front line
At ESMO, AstraZeneca/Daiichi Sankyo and Gilead disclosed Phase 3 antibody‑drug conjugate (ADC) data competing for first‑line use in metastatic triple‑negative breast cancer (TNBC) for patients...
Enhertu shows benefit in earlier breast cancer — Phase 3 data
AstraZeneca and Daiichi Sankyo presented Phase 3 data showing Enhertu (trastuzumab deruxtecan) can improve outcomes when used earlier in breast cancer, potentially moving the ADC into...
Exelixis’ zanzalintinib plus Tecentriq cuts death risk 20% in colorectal cancer
Exelixis reported Phase 3 results showing its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced the risk of death by roughly 20% versus a Stivarga‑based regimen in previously treated...
Padcev plus Keytruda extends survival in Phase 3 bladder cancer
New Phase 3 data showed the antibody‑drug conjugate Padcev (enfortumab vedotin) combined with Merck’s Keytruda (pembrolizumab) extended survival in locally advanced or metastatic bladder cancer...
BioCryst buys Astria for $700M — gains Phase 3 HAE asset
BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics for about $700 million to add navenibart, a Phase 3 candidate for hereditary angioedema (HAE), MedCity News reported. The move...
mRNA COVID shots appear to boost checkpoint immunotherapy outcomes
Clinical centers including MD Anderson reported retrospective analyses suggesting patients who received an mRNA COVID‑19 vaccine within roughly 100 days of starting checkpoint inhibitors lived...
Eli Lilly’s VC arm leads $45M into anti‑aging biotech NewLimit
NewLimit raised $45 million in a financing round that included Lilly Ventures and S32, the company said. The funding will support clinical development of NewLimit’s programs targeting age‑related...
Anthropic rolls into life sciences — GenAI adoption accelerates in pharma
Anthropic announced a first dedicated life‑sciences product and a new team to accelerate applications of the company’s large‑language models in biology, including drug discovery and lab...
FDA approves Roche’s Gazyva: new option for lupus nephritis
The FDA granted approval to Roche’s anti-CD20 antibody Gazyva for patients with lupus nephritis, expanding treatment options for a severe form of systemic lupus that affects the kidneys. Roche...
Exelixis TKI trims death risk 20% — Phase 3 readout
Exelixis reported Phase 3 data showing its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced the risk of death by 20% versus the Stivarga comparator in previously treated metastatic...
ADC showdown: Datroway and Trodelvy produce competing Phase 3 results
At ESMO, AstraZeneca/Daiichi Sankyo’s Datroway and Gilead’s Trodelvy both reported Phase 3 results for advanced triple-negative breast cancer, setting up a head-to-head efficacy and positioning...
Enhertu moves earlier — ADCs shifting into curative settings
AstraZeneca and Daiichi Sankyo disclosed data showing Enhertu has benefit when given earlier in breast cancer, supporting the drug’s move into potentially curative settings. Presentations at ESMO...
Padcev–Keytruda combo extends survival in bladder cancer
New Phase 3 data showed the antibody‑drug conjugate Padcev combined with Keytruda improved survival outcomes in locally advanced or metastatic bladder cancer. The readout, presented at ESMO,...
Boehringer, Bayer neck-and-neck in front-line HER2‑mutant lung
Boehringer Ingelheim and Bayer presented front-line data for targeted therapies in HER2‑mutant lung cancer at ESMO, with each company reporting tumor shrinkage and clinical activity in...
First‑in‑class YAP‑TEAD inhibitor shows early mesothelioma activity
Investigators at MD Anderson reported early clinical activity for VT3989, a first‑in‑class YAP–TEAD inhibitor, in heavily pretreated patients with refractory mesothelioma and other solid tumors....
BioCryst shells out $700M for Astria to chase HAE market
BioCryst agreed to acquire Astria Therapeutics for $700 million, adding navenibart—a Phase 3 injectable antibody for hereditary angioedema—to its pipeline. Management framed the deal as a bid to...